BiotechTube
Endolastic

Endolastic

Austin, United States· Est.
endolastic.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Endolastic is a private, pre-revenue medical device company advancing its EndoBand™ platform for endoscopic, band-based interventions. With over 50 successful human cases using its first-generation device, the company is preparing for commercial launch and regulatory filings, supported by a $4M physician-led seed round. Its technology aims to offer a durable, anatomical solution for GERD, obesity, and diabetes, positioned between pharmaceutical therapies and invasive surgery in terms of efficacy, cost, and procedural simplicity.

Gastroesophageal Reflux Disease (GERD)ObesityType 2 Diabetes

Technology Platform

EndoBand™ ligation-based platform utilizing proprietary elastomeric bands (WindowLock™ design) for endoscopic tissue capture, controlled ischemia, and natural regeneration to achieve durable anatomical reshaping.

Opportunities

Endolastic operates in massive markets (GERD, obesity, diabetes) where current solutions have significant drawbacks.
Its platform offers a potential best-of-both-worlds solution: outpatient procedural simplicity with surgery-like durability, positioning it favorably between drugs and invasive surgery.
The single platform for multiple indications creates commercial and operational synergies.

Risk Factors

The company faces significant regulatory risk as all programs are pending FDA approval.
Clinical risk remains as larger, controlled trials are needed beyond initial case series.
It also faces intense competition from established endoscopic devices, pharmaceuticals (e.g., GLP-1s), and surgery, requiring clear differentiation and successful reimbursement.

Competitive Landscape

Endolastic competes with endoscopic device companies like Apollo Endosurgery (OverStitch for ESG) and GERD treatment devices (e.g., for TIF), as well as the dominant pharmaceutical paradigm of GLP-1 receptor agonists for obesity/diabetes. Its key differentiators are the ligation-based mechanism, claimed superior efficacy/safety profile in early data, and platform versatility across multiple GI indications.

More companies in Drug Delivery & Formulation →More companies in United States →